DNA

Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency

Interim Data from Phase 1 Proof-of-Concept Arm Indicates CDX-7108 Improves Lipid AbsorptionREDWOOD CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) --...

uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Event theme, “MS: Going Viral” touches on the role of viruses in MS, particularly Epstein-Barr, a topic related to Company’s...

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress

Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatment for hereditary angioedema (HAE)Submitted IND application for...

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023

BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...

New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology

Featured presentation on the time to clinical benefit of sotagliflozin in people with worsening heart failureTHE WOODLANDS, Texas, Feb. 20,...

Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR

Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer

Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...

RadioMedix Inc. Announces the Acquisition of its 225Ac-PSMA I&T program, a Targeted Alpha Therapy (TAT) for Metastatic Castration Resistant Prostate Cancer, by Fusion Pharmaceuticals Inc.

Houston, TX, Feb. 15, 2023 (GLOBE NEWSWIRE) -- RadioMedix, Inc. (“RadioMedix” or “Company”), a clinical-stage radiopharmaceutical company announced the acquisition...

error: Content is protected !!